200 related articles for article (PubMed ID: 31250007)
1. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B
Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007
[No Abstract] [Full Text] [Related]
2. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
3. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
LoPiccolo J; Schollenberger MD; Dakhil S; Rosner S; Ali O; Sharfman WH; Silk AW; Bhatia S; Lipson EJ
J Immunother Cancer; 2019 Jul; 7(1):170. PubMed ID: 31287031
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
6. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
Michalarea V; Fontana E; Garces AI; Williams A; Smyth EC; Picchia S; Rao S; Chau I; Cunningham D; Bali MA
Curr Probl Cancer; 2019 Oct; 43(5):487-494. PubMed ID: 30827742
[TBL] [Abstract][Full Text] [Related]
8. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
9. In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series.
Xu MJ; Wu S; Daud AI; Yu SS; Yom SS
J Immunother Cancer; 2018 May; 6(1):43. PubMed ID: 29848371
[TBL] [Abstract][Full Text] [Related]
10. Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD-1/PD-L1-refractory Merkel cell carcinoma-a case report.
Leven AS; Becker JC; Pöttgen C; Schadendorf D; Ugurel S; Tasdogan A
Int J Dermatol; 2024 Feb; 63(2):e69-e71. PubMed ID: 38093413
[No Abstract] [Full Text] [Related]
11. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
Marchand A; Kervarrec T; Bhatia S; Samimi M
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
[TBL] [Abstract][Full Text] [Related]
12. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
13. Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?
Dasanu CA; Del Rosario M; Codreanu I; Hyams DM; Plaxe SC
J Oncol Pharm Pract; 2019 Jan; 25(1):214-216. PubMed ID: 29933728
[TBL] [Abstract][Full Text] [Related]
14. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
[TBL] [Abstract][Full Text] [Related]
15. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma.
Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934
[No Abstract] [Full Text] [Related]
16. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
17. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma.
Damlaj M; Alzayed M; Alahmari B; Alhejazi A; Alaskar A; Alzahrani M
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e559-e563. PubMed ID: 31377210
[No Abstract] [Full Text] [Related]
19. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
20. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
Martini DJ; Hamieh L; McKay RR; Harshman LC; Brandao R; Norton CK; Steinharter JA; Krajewski KM; Gao X; Schutz FA; McGregor B; Bossé D; Lalani AA; De Velasco G; Michaelson MD; McDermott DF; Choueiri TK
Cancer Immunol Res; 2018 Apr; 6(4):402-408. PubMed ID: 29437040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]